Front Page News
Seven Individuals and Families Recognized for Their Contributions to the Community
Each year, while much of our community is gathered together, we use the Annual SMA Conference to recognize several individuals, families and foundations who have […]
Read More ›Cytokinetics Releases Update on Phase 1 Trial at Annual SMA Conference
At last week’s Annual SMA Conference, Cytokinetics released additional data from their Phase 1 study of CK-2127107, a skeletal muscle activator. Cytokinetics, in partnership with […]
Read More ›Isis Announces Additional Trial Results at Annual SMA Conference
At last week’s Annual SMA Conference, Isis Pharmaceuticals, Inc. provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase […]
Read More ›Cure SMA Announces Nearly $2 Million in New Planned Research Funding
Cure SMA has announced plans to fund $1.995 million in new research grants over the next several months. This includes funding for all four areas […]
Read More ›Dr. Mary Schroth Joins Cure SMA as Medical Professional Education Consultant
We are very excited to announce that Dr. Mary Schroth has joined us as our medical professional education consultant. She will be working with us […]
Read More ›Read the Summer 2015 Issue of Compass
The latest issue of Compass, our research publication, is now available online. This summer 2015 issue includes information on our recent drug discovery grants, plus […]
Read More ›The 2015 Annual SMA Conference is Here!
The 26th Annual SMA Conference kicks off tomorrow with our Newly Diagnosed Program, and continues into the weekend with all of our usual programs that […]
Read More ›2015 Annual SMA Conference Exhibitors
Thank you to the following exhibitors who have generously supported our 2015 Annual SMA Conference. This one-of-a-kind event would not be possible without your support! […]
Read More ›Cure SMA Releases New Clinical Trial Care Series Booklet
As more and more SMA drug programs progress through clinical trials, there is an increasing need for accurate and unbiased information on clinical trials from […]
Read More ›Isis Releases Encouraging Results from Phase 2 Study
Isis Pharmaceuticals provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type I spinal muscular atrophy (SMA). Previously […]
Read More ›